Bioaegis Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
Phase 2
Not yet recruiting
- Conditions
- Decompression Sickness
- Interventions
- Drug: Sodium Chloride 0.9% Inj pre-exposureDrug: Sodium Chloride 0.9% Inj post-exposureDrug: Recombinant human plasma gelsolin post-exposureDrug: Recombinant human plasma gelsolin pre-exposureOther: Hyperbaric chamber
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06216366
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Phase 2
Recruiting
- Conditions
- InfectionsAcute Respiratory Distress Syndrome
- Interventions
- Drug: normal saline
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05947955
- Locations
- 🇺🇸
University of Louisville-Jewish Hospital, Louisville, Kentucky, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸McGovern Medical School - UT Physicians Pulmonary Medicine - Texas Medical Center, Houston, Texas, United States
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Phase 1
Completed
- Conditions
- HealthyVolunteers
- Interventions
- Other: placebo
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05789745
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
Rhu-pGSN for Severe Covid-19 Pneumonia
Phase 2
Completed
- Conditions
- Sars-CoV2
- Interventions
- Other: PlaceboDrug: Recombinant human plasma gelsolin (Rhu-pGSN)
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04358406
- Locations
- 🇪🇸
Sant Joan de Reus SAM University Hospital, Reus, Spain
🇪🇸Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
🇷🇴Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie, Timişoara, Romania
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Phase 1
Completed
- Conditions
- Community-acquired Pneumonia
- Interventions
- Other: Normal Saline Placebo
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03466073
- Locations
- 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇬🇪JSC Rustavi Central Hospital, Rustavi, Georgia
🇬🇪LTD Central University Clinic After Academic N. Kipshidze, Tbilisi, Georgia
© Copyright 2025. All Rights Reserved by MedPath